Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 10/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 4/20 | 0.38 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6513255 | 0.89 | FGFR1 (0.42) | FGFR1METKDRGCKFGFR2 | |
| SCHEMBL6038823 | 0.89 | FGFR1 (0.44) | FGFR1KDRGCKBRAFFGFR2 | |
| SCHEMBL5114627 | 0.87 | FGFR1 (0.43) | FGFR1GCKBRAFFGFR3 | |
| SCHEMBL5108431 | 0.87 | FGFR1 (0.42) | FGFR1METBRAFFGFR3 | |
| SCHEMBL5104756 | 0.84 | DYRK3 (0.43) | FGFR1KDRMAPK13DYRK3DYRK1A | |
| SCHEMBL13999495 | 0.83 | MET (0.42) | FGFR1METKDRFGFR3 | |
| SCHEMBL1248303 | 0.83 | FGFR1 (0.48) | FGFR1FGFR3 | |
| SCHEMBL5109113 | 0.81 | KDR (0.44) | FGFR1KDRDYRK1AFGFR3 | |
| SCHEMBL5102211 | 0.81 | FGFR1 (0.43) | FGFR1KDRFGFR3 | |
| SCHEMBL13999494 | 0.81 | GCK (0.53) | FGFR1GCKFGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060281185-A1 | Detection of analytes in aqueous environments | SENSORS FOR MEDICINE AND SCIENCE, INC. (US) | 2006-12-14 | — | — | US | disclosed |
| US-20060004029-A1 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1522540-A1 | AZAARENE DERIVATIVES | Eisai Co., Ltd. (JP) | 2005-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281185-A1 | Detection of analytes in aqueous environments | MPI, NEFM, CD44 | FGFR1 2225/4885MET 1569/4885KDR 1556/4885 |
| US-20060004029-A1 | Nitrogen-containing aromatic derivatives | NR0B2, NR0B1, NR4A1 | FGFR1 595/4885MET 814/4885KDR 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.